

## **Annual General Meeting Date**

Melbourne, Australia, 4 September 2025: In accordance with ASX Listing Rule 3.13.1, 4DMedical Limited (ASX: 4DX, "4DMedical", or the "Company"), advises that its next Annual General Meeting ("AGM") will be held at 12:00pm (AEDT) on Thursday 30 October 2025. An election of directors will be held at this AGM pursuant to ASX Listing Rule 14.5. Details of the Directors to be elected will be included in the forthcoming Notice of AGM.

The Closing Date for receipt of nominations for the position of Director is 11 September 2025. Any nominations must be received in writing by no later than 5:00pm AEST on this date at the Company's Registered Office.

## -ENDS-

Authorised by the 4DMedical Board of Directors.

## **Contacts**

| Corporate                        | Administration                 | Media Enquiries       |
|----------------------------------|--------------------------------|-----------------------|
| Investor Relations               | Company Secretary              | 4Dmedia@4dmedical.com |
| investor.relations@4dmedical.com | companysecretary@4dmedical.com |                       |

## **About 4DMedical**

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™, and the ground-breaking CT:VQ™ solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com